Academic Radiology
Volume 16, Issue 5 , Pages 627-637 , May 2009

Nanodelivery of MRI Contrast Agent Enhances Sensitivity of Detection of Lung Cancer Metastases

Received 13 November 2007 ,Accepted 15 December 2008.

References 

  1. American Cancer Society. Cancer facts and figures 2008. Available online at:http://www.cancer.org.
  2. Gohagan J, Marcus P, Fagerstrom R, et al. Writing Committee LSSRG. Baseline findings of a randomized feasibility trial of lung cancer screening with spiral CT scan vs chest radiograph: the Lung Screening Study of the National Cancer Institute. Chest. 2004;126:114–121
  3. Gohagan JK, Marcus PM, Fagerstrom RM, et al. Final results of the Lung Screening Study, a randomized feasibility study of spiral CT versus chest X-ray screening for lung cancer. Lung Cancer. 2005;47:9–15
  4. International Early Lung Cancer Action ProgramHenschke CI, Yankelevitz DF, et al. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med. 2006;355:1763–1771
  5. Stitik FP, Tockman MS. Radiographic screening in the early detection of lung cancer. Radiol Clin N Am. 1978;16:347–366
  6. Stitik FP, Tockman MS, Khouri N. Chest radiology. In:  Miller AB editors. Screening for cancer. New York: Academic Press; 1985;p. 163–191
  7. Swensen SJ, Jett JR, Hartman TE, et al. Lung cancer screening with CT: Mayo Clinic experience. Radiology. 2003;226:756–761
  8. Swensen SJ, Jett JR, Hartman TE, et al. CT screening for lung cancer: five-year prospective experience. Radiology. 2005;235:259–265
  9. Pinsky PF, Marcus PM, Kramer BS, et al. Diagnostic procedures after a positive spiral computed tomography lung carcinoma screen. Cancer. 2005;103:157–163
  10. Brenner DJ, Hall EJ. Computed tomography: an increasing source of radiation exposure. N Engl J Med. 2007;357:2277–2284
  11. Bozcuk H, Martin C. Does treatment delay affect survival in non-small cell lung cancer? A retrospective analysis from a single UK centre. Lung Cancer. 2001;34:243–252
  12. Pita-Fernandez S, Montero-Martinez C, Pertega-Diaz S, et al. Relationship between delayed diagnosis and the degree of invasion and survival in lung cancer. J Clin Epidemiol. 2003;56:820–825
  13. Quarterman RL, McMillan A, Ratcliffe MB, et al. Effect of preoperative delay on prognosis for patients with early stage non-small cell lung cancer. [see comment] J Thorac Cardiovasc Surg. 2003;125:108–113
  14. Kashiwabara K, Koshi S, Itonaga K, et al. Outcome in patients with lung cancer found on lung cancer mass screening roentgenograms, but who did not subsequently consult a doctor. Lung Cancer. 2003;40:67–72
  15. Yoshimoto A, Tsuji H, Takazakura E, et al. Reasons for the delays in the definitive diagnosis of lung cancer for more than one year from the recognition of abnormal chest shadows. Intern Med. 2002;41:95–102
  16. Aragoneses FG, Moreno N, Leon P, et al. Influence of delays on survival in the surgical treatment of bronchogenic carcinoma. Lung Cancer. 2002;36:59–63
  17. Myrdal G, Lambe M, Hillerdal G, et al. Effect of delays on prognosis in patients with non-small cell lung cancer. Thorax. 2004;59:45–49
  18. Tammemagi M, Freedman MT, Oken M, et al. Factors associated with human small aggressive non-small cell lung cancer. Cancer Epidemiol Biomark Prevent. 2007;16:2082–2089
  19. Bach PB, Jett JR, Pastorino U, et al. Computed tomography screening and lung cancer outcomes. JAMA. 2007;297:953–961
  20. Pirollo KF, Dagata J, Wang P, et al. A tumor-targeted nanodelivery system to improve early MRI detection of cancer. Mole Imaging. 2006;5:41–52
  21. Xu L, Pirollo K, Tang W-H, et al. Transferrin-liposome-mediated systemic p53 gene therapy in combination with radiation results in regression of human head and neck cancer xenografts. Human Gene Ther. 1999;10:2941–2952
  22. Xu L, Pirollo K, Rait A, et al. Systemic p53 gene therapy in combination with radiation results in human tumor regression. Tumor Target. 1999;4:92–104
  23. Xu L, Tang W, Huang C, et al. Anti-transferrin receptor ScFv-targeted immunolipoplexes for systemic cancer gene therapy. Mole Med. 2001;10:723–734
  24. Xu L, Huang C-C, Huang W-Q, et al. Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes. Mole Cancer Ther. 2002;1:337–346
  25. Rait AS, Pirollo KF, Xiang L, et al. Tumor-targeting, systemically delivered antisense HER-2 chemosensitizes human breast cancer xenografts irrespective of HER-2 levels. Mol Med. 2002;8:475–486
  26. Rait AS, Pirollo KF, Ulick D, et al. HER-2-targeted antisense oligonucleotide results in sensitization of head and neck cancer cells to chemotherapeutic agents. Ann N Y Acad Sci. 2003;1002:78–89
  27. Pirollo KF, Zon G, Rait A, et al. Tumor-targeting nanoimmunoliposome complex for short interfering RNA delivery. Human Gene Ther. 2006;17:117–124
  28. Pirollo KF, Rait A, Zhou Q, et al. Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system. Cancer Res. 2007;67:2938–2943
  29. Yu W, Pirollo KF, Yu B, et al. Enhanced transfection efficiency of a systemically delivered tumor-targeting immunolipoplex by inclusion of a pH-sensitive histidylated oligolysine peptide. Nucl Acids Res. 2004;32:e48
  30. Keer HN, Kozlowski JM, Tsai YC, et al. Elevated transferrin receptor content in human prostate cancer cell lines assessed in vitro and in vivo. J Urol. 1990;143:381–385
  31. Rossi MC, Zetter BR. Selective stimulation of prostatic carcinoma cell proliferation by transferrin. Proc Natl Acad Sci U S A. 1992;89:6197–6201
  32. Elliott RL, Elliott MC, Wang F, et al. Breast carcinoma and the role of iron metabolism. A cytochemical, tissue culture, and ultrastructural study. Ann N Y Acad Sci. 1993;698:159–166
  33. Thorstensen K, Romslo I. The transferrin receptor: its diagnostic value and its potential as therapeutic target. Scand J Clin Lab Investig Suppl. 1993;215:113–120
  34. Miyamoto T, Tanaka N, Eishi Y, et al. Transferrin receptor in oral tumors. Int J Oral Maxillofac Surg. 1994;23:430–433
  35. Whitney JF, Clark JM, Griffin TW, et al. Transferrin receptor expression in nonsmall cell lung cancer. Histopathol Clin Correlates. 1995;76:20–25
  36. Chakrabarty A, Hillman GG, Maughan RL, et al. Influence of tumor site on the therapy of murine kidney cancer. Anticancer Res. 1994;14:373–378
  37. Salup RR, Herberman RB, Chirigos MA, et al. Therapy of peritoneal murine cancer with biological response modifiers. J Immunopharmacol. 1985;7:417–436
  38. Oken MM, Marcus PM, Hu P, et al. Baseline chest radiograph for lung cancer detection in the randomized Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. J Natl Cancer Inst. 2005;97:1832–1839
  39. Centers for Disease Control and Prevention (CDC) . Recent trends in mortality rates for four major cancers, by sex and race/ethnicity—United States, 1990–1998. MMWR Morbid Mortal Wkly Rep. 2002;51:49–53
  40. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest. 1997;111:1710–1717
  41. Swensen SJ. Functional CT: lung nodule evaluation. Radiographics. 2000;20:1178–1181
  42. Swensen SJ, Viggiano RW, Midthun DE, et al. Lung nodule enhancement at CT: multicenter study. Radiology. 2000;214:73–80
  43. Swensen SJ, Brown LR, Colby TV, et al. Pulmonary nodules: CT evaluation of enhancement with iodinated contrast material. Radiology. 1995;194:393–398
  44. Swensen SJ, Brown LR, Colby TV, et al. Lung nodule enhancement at CT: prospective findings. Radiology. 1996;201:447–455
  45. Jeong YJ, Lee KS, Jeong SY, et al. Solitary pulmonary nodule: characterization with combined wash-in and washout features at dynamic multi-detector row CT. Radiology. 2005;237:675–683
  46. Zhang M, Kono M. Solitary pulmonary nodules: evaluation of blood flow patterns with dynamic CT. Radiology. 1997;205:471–478
  47. Maki DD, Gefter WB, Alavi A. Recent advances in pulmonary imaging. Chest. 1999;116:1388–1402
  48. Page D. The strange courtship of astronomy and mammography. Digital Imaging Mag. December 1995;

 Supported in part by STTR Phase I grant 1R41 CA 121453-01 (E.H.C., M.F., K.F.P.), and a research grant from SynerGene Therapeutics (K.F.P.). These studies were conducted in part using the Histopathology and Tissue, and Animal Core Facilities supported by NCI Cancer Center Support grant and USPHS grant 2P30-CA-51008 and 1 S10 RR 15768-01. This investigation was conducted in part in a facility constructed with support from Research Facilities Improvement grant C06RR14567 from the National Center for Research Resources, National Institutes of Health, Bethesda, MD.

PII: S1076-6332(08)00742-3

doi: 10.1016/j.acra.2008.12.002

Academic Radiology
Volume 16, Issue 5 , Pages 627-637 , May 2009

Article Tools

* Image Usage & Resolution